Semax ou Selank : ce qui les distingue réellement

Recherche cognitive et nootropique

Semax and Selank get compared constantly, and the comparison is slightly misleading. They came out of the same Russian institute, they were built using the same stabilising trick, and they are sold side by side everywhere. But they are derived from unrelated parent molecules and are studied around different systems. Asking which is better is a bit like asking whether a throttle is better than a brake.

The short version

	Semax	Selank
Derived from	ACTH(4–10) fragment	Tuftsin
Parent molecule’s day job	Adrenal hormone signalling	Immune signalling
Main research theme	BDNF, neurotrophic signalling, plasticity	GABAergic modulation, enkephalinase inhibition
Studied in	Stroke, brain injury, attention and memory models	Anxiety and stress models
Loose characterisation	The activating side	The calming side
Russian clinical status	Registered; essential medicines list	In clinical use since the 1990s

What they genuinely share

Three things, and they are the reason the two are permanently linked:

• The same institute. Both came out of Russian neuropeptide research programmes in the same era.
• The same stabilising design. Each takes a fragile natural fragment and attaches a Pro-Gly-Pro sequence to protect it from the enzymes that would otherwise destroy it within minutes. That is a design decision, not a mechanism.
• The same delivery question. Both are studied predominantly as intranasal formulations, for the same reason — peptides cross the blood–brain barrier poorly.

What they do not share is a receptor, a pathway, or a research literature. The shared surname is chemistry, not biology.

Where they diverge

Semax: the plasticity arm

The consistent thread through the Semax literature is BDNF — brain-derived neurotrophic factor — and its TrkB receptor. BDNF is the protein most closely associated in neuroscience with synaptic plasticity, meaning the brain’s capacity to strengthen and reorganise connections. The Semax work sits on top of an original programme aimed at ischaemic stroke, which is why a surprising amount of it is neuroprotection research rather than cognitive-enhancement research.

Selank: the inhibitory arm

Selank’s literature centres on GABAergic modulation — GABA being the brain’s main inhibitory signal — and on inhibiting the enzymes that break down enkephalins, the body’s own short opioid-like signalling peptides. The clinical use in Russia is for anxiety rather than cognition. Its defining design claim was anxiolytic activity without sedation, which is the specific thing that made it interesting.

Why they are studied together

The pairing has a community nickname — the Russian nootropic stack — and the rationale behind it is the same rationale behind any sensible peptide stack: the two compounds address different, non-overlapping parts of one system.

Put simply, one is studied around excitatory and plasticity signalling and the other around inhibitory and stress signalling. Compounds that pull on separate levers are more interesting to study together than compounds that pull on the same one, where you cannot tell which is responsible for what you observe. Pairing two GABAergic compounds tells you very little; pairing a plasticity-oriented compound with an inhibitory one at least gives you two distinguishable variables.

A third component: Cerebrolysin

Where a stack extends beyond the two, the usual third is Cerebrolysin — a mixture of low-molecular-weight peptides derived from porcine brain tissue, studied as a broad neurotrophic-factor mimetic.

It is worth knowing because it changes the evidence picture. Unusually for this category, Cerebrolysin has been through real international randomised controlled trials in dementia, stroke and traumatic brain injury. The results across those trials are genuinely mixed and the compound remains contested — but the trials exist, were run outside Russia, and are published in journals anyone can read. That is more than can be said for most of the category.

Which one, if you are only picking one

This is a research-design question rather than a shopping question, and the honest answer is that it depends on what is being investigated. Semax is the one with the neurotrophic and plasticity literature behind it; Selank is the one with the anxiolytic and stress literature. Neither is a stronger compound than the other in any general sense — they have barely been compared head to head, because they were never developed to do the same job.

The evidence caveat that applies to both

Both compounds have a longer human clinical history than almost anything else in the research-peptide category, and both have far less independent verification than any approved Western medicine. The trials are small, largely Russian, and rarely replicated by outside groups. Neither is approved in Canada, and Health Canada has assessed neither for safety or efficacy.

That combination — real clinical history, limited independent scrutiny — is unusual, and it is the single most important thing to understand about this pair. It is also why the marketing around them tends to be so overheated in both directions.

The reason no Western sponsor has taken either compound through trials is not scientific but economic, and it applies across most of this category: why peptides like these never reach approval.

Frequently asked questions

What is the difference between Semax and Selank?

Semax is derived from an ACTH fragment and is studied around BDNF, neurotrophic signalling and plasticity. Selank is derived from tuftsin and is studied around GABAergic modulation and anxiety models. They share a research lineage and a stabilising design, not a mechanism.

Can Semax and Selank be studied together?

They are frequently paired in research settings because they address separate, non-overlapping systems. However, there is very little published work on the combination itself — the rationale is inferred from what is known about each compound individually.

Which is better, Semax or Selank?

Neither, in any general sense. They were developed for different purposes and have barely been compared directly. Which is more relevant depends entirely on what is being investigated.

Is Selank a sedative and Semax a stimulant?

Neither description is accurate. Selank was specifically designed for anxiolytic activity without sedation, and Semax has no stimulant-class mechanism. The activating and calming characterisations are loose shorthand for which systems each is studied around.

Are Semax and Selank approved in Canada?

No. Neither holds Canadian marketing authorisation and Health Canada has not assessed either compound. Both are supplied as research materials for laboratory use only.

References

Semax has human research, mostly small studies concentrated in Russian-language literature rather than large modern placebo-controlled trials.

1. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]Gusev EI et al. · Zh Nevrol Psikhiatr Im S S Korsakova 2018 · PMID 29798983Clinical study of 110 people after ischaemic stroke, with and without Semax; not a large modern placebo-controlled randomised trial.
2. Effects of Semax on the Default Mode Network of the BrainLebedeva IS et al. · Bull Exp Biol Med 2018 · PMID 30225715Small human study; 24 healthy volunteers, intranasal Semax versus placebo, resting-state fMRI. Mechanistic — does not establish improved cognition.
3. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]Gusev EI et al. · Zh Nevrol Psikhiatr Im S S Korsakova 1997 · PMID 11517472Clinical study; 30 acute ischaemic stroke patients against an 80-patient conventional-treatment control cohort.

Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.